EMA to review safety of somatropin
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has today said that it will reassess the benefit:risk balance of medicines containing the human growth hormone somatropin. The move comes in response to a long-term study in patients treated during childhood with somatropin, which suggests that the drug carries a higher risk of mortality compared with the general population.